PT2776567T - Composições e métodos para o tratamento de citomegalovírus - Google Patents

Composições e métodos para o tratamento de citomegalovírus

Info

Publication number: PT2776567T
Authority: PT; Portugal
Prior art keywords: cytomegalovirus; compositions; treatment; methods
Prior art date: 2011-11-11

Application number

PT128475597T

Other languages

English (en)

Original Assignee

Variation Biotechnologies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-11

Filing date

2012-11-09

Publication date

2021-05-25

2012-11-09 Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc

2021-05-25 Publication of PT2776567T publication Critical patent/PT2776567T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20245—Special targeting system for viral vectors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Lubricants (AREA)

PT128475597T 2011-11-11 2012-11-09 Composições e métodos para o tratamento de citomegalovírus PT2776567T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161558800P	2011-11-11	2011-11-11
US201261654157P	2012-06-01	2012-06-01

Publications (1)

Publication Number	Publication Date
PT2776567T true PT2776567T (pt)	2021-05-25

Family

ID=48290708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT128475597T PT2776567T (pt)	2011-11-11	2012-11-09	Composições e métodos para o tratamento de citomegalovírus

Country Status (14)

Country	Link
US (3)	US9777043B2 (pt)
EP (2)	EP2776567B1 (pt)
JP (2)	JP6232544B2 (pt)
KR (2)	KR102340558B1 (pt)
CN (3)	CN111995664B (pt)
AU (3)	AU2012335277B2 (pt)
BR (2)	BR122019027913B1 (pt)
CA (2)	CA3166278A1 (pt)
DK (1)	DK2776567T3 (pt)
ES (1)	ES2874233T3 (pt)
MX (1)	MX353189B (pt)
PT (1)	PT2776567T (pt)
RU (2)	RU2737530C1 (pt)
WO (1)	WO2013068847A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9575055B2 (en)	2009-06-18	2017-02-21	Kiyatec Inc.	Co-culture bioreactor system
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (pt)	2010-10-01	2019-09-24	Moderna Therapeutics Inc	ácidos nucleicos manipulados e métodos de uso dos mesmos.
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR102014061B1 (ko)	2011-10-03	2019-08-28	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
ES2874233T3 (es) *	2011-11-11	2021-11-04	Variation Biotechnologies Inc	Composiciones y métodos para el tratamiento de citomegalovirus
RS63244B1 (sr)	2011-12-16	2022-06-30	Modernatx Inc	Kompozicije modifikovane mrna
JP6265344B2 (ja) *	2012-03-27	2018-01-24	ヴァリエーションバイオテクノロジーズインコーポレイテッド	抗サイトメガロウイルス中和抗体の検出方法
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9192651B2 (en)	2012-04-02	2015-11-24	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of secreted proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6294890B2 (ja) *	2012-10-30	2018-03-14	ファイザー・インク	ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
US9597380B2 (en)	2012-11-26	2017-03-21	Modernatx, Inc.	Terminally modified RNA
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP3052106A4 (en)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
DK3158058T3 (da)	2014-06-18	2019-07-01	Morphosys Ag	Fusionsproteiner og bruger deraf
KR101678740B1 (ko) *	2014-10-24	2016-11-23	단국대학교 천안캠퍼스 산학협력단	세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) *	2015-03-16	2016-09-22	The Broad Institute, Inc.	Constructs for continuous monitoring of live cells
US10968253B2 (en) *	2015-10-20	2021-04-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods and products for genetic engineering
JP6921833B2 (ja)	2015-10-22	2021-08-18	モデルナティーエックス，インコーポレイテッド	ヒトサイトメガロウイルスワクチン
US10611800B2 (en)	2016-03-11	2020-04-07	Pfizer Inc.	Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) *	2016-03-21	2017-09-28	Biontech Rna Pharmaceuticals Gmbh	Trans-replicating rna
EP3528821A4 (en) *	2016-10-21	2020-07-01	ModernaTX, Inc.	VACCINE AGAINST THE HUMANE CYTOMEGALOVIRUS
EP3784276A4 (en) *	2018-04-24	2022-03-16	Merck Sharp & Dohme Corp.	SCALABLE CHROMATOGRAPHY PROCEDURE FOR PURIFICATION OF HUMAN CYTOMEGALOVIRUS
SG11202010821TA (en) *	2018-05-04	2020-11-27	Spybiotech Ltd	Vaccine composition
US11629172B2 (en)	2018-12-21	2023-04-18	Pfizer Inc.	Human cytomegalovirus gB polypeptide
CA3142110A1 (en) *	2019-05-31	2020-12-03	Variation Biotechnologies Inc.	Immunotherapeutic compositions for treatment of glioblastoma multiforme
CA3092525A1 (en) *	2019-09-09	2021-03-09	Glaxosmithkline Biologicals S.A.	Immunotherapeutic compositions
US11857622B2 (en)	2020-06-21	2024-01-02	Pfizer Inc.	Human cytomegalovirus GB polypeptide
US11406703B2 (en)	2020-08-25	2022-08-09	Modernatx, Inc.	Human cytomegalovirus vaccine
CN115948468A (zh) *	2022-09-09	2023-04-11	青岛大学	一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) *	2023-06-02	2024-12-05	Variation Biotechnologies Inc.	Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267965B1 (en)	1981-12-24	2001-07-31	Virogenetics Corporation	Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) *	1984-10-26	1986-05-22	Green Cross Corp:The	ＨＢｓＡｇの精製方法
ATE246244T1 (de) *	1988-01-29	2003-08-15	Aventis Pasteur	Rekombinante cmv-neutralisierungsproteine
US5500161A (en)	1993-09-21	1996-03-19	Massachusetts Institute Of Technology And Virus Research Institute	Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) *	1998-11-26	2006-02-02	Heinrich-Pette-Institut	Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de)	1999-03-08	2000-09-14	Bodo Plachter	Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
BR0014408A (pt) *	1999-09-30	2002-07-02	Univ Washington	Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
EP1201750A1 (en) *	2000-10-26	2002-05-02	Genopoietic	Synthetic viruses and uses thereof
US9045727B2 (en) *	2002-05-17	2015-06-02	Emory University	Virus-like particles, methods of preparation, and immunogenic compositions
AU2003301148A1 (en)	2002-12-23	2004-07-22	Vical Incorporated	Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US7419674B2 (en)	2003-07-11	2008-09-02	Alpha Vax, Inc.	Alpha virus-based cytomegalovirus vaccines
RU2290204C1 (ru) *	2005-07-27	2006-12-27	Общество с ограниченной ответственностью "Аванген"	Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
JP2009544322A (ja)	2006-07-27	2009-12-17	リゴサイトファーマシューティカルズインコーポレイテッド	キメラウイルス様粒子
US20090123494A1 (en)	2007-07-31	2009-05-14	William Staplin	Momlv-based pseudovirion packaging cell line
US20110250675A1 (en)	2008-03-26	2011-10-13	Life Technologies Corporaiton	Virus-Like Particle Mediated Cellular Delivery
GB0907935D0 (en) *	2009-05-08	2009-06-24	Henderson Morley Plc	Vaccines
ES2874233T3 (es)	2011-11-11	2021-11-04	Variation Biotechnologies Inc	Composiciones y métodos para el tratamiento de citomegalovirus
WO2015089340A1 (en) *	2013-12-11	2015-06-18	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

2012
- 2012-11-09 ES ES12847559T patent/ES2874233T3/es active Active
- 2012-11-09 RU RU2014123465A patent/RU2737530C1/ru active
- 2012-11-09 BR BR122019027913-6A patent/BR122019027913B1/pt active IP Right Grant
- 2012-11-09 DK DK12847559.7T patent/DK2776567T3/da active
- 2012-11-09 EP EP12847559.7A patent/EP2776567B1/en active Active
- 2012-11-09 CA CA3166278A patent/CA3166278A1/en active Pending
- 2012-11-09 US US14/357,423 patent/US9777043B2/en active Active
- 2012-11-09 KR KR1020197025818A patent/KR102340558B1/ko active IP Right Grant
- 2012-11-09 KR KR1020147015909A patent/KR102301463B1/ko active IP Right Grant
- 2012-11-09 AU AU2012335277A patent/AU2012335277B2/en active Active
- 2012-11-09 WO PCT/IB2012/002854 patent/WO2013068847A2/en active Application Filing
- 2012-11-09 CN CN202010272504.4A patent/CN111995664B/zh active Active
- 2012-11-09 PT PT128475597T patent/PT2776567T/pt unknown
- 2012-11-09 RU RU2019139064A patent/RU2019139064A/ru unknown
- 2012-11-09 EP EP21152309.7A patent/EP3854416A1/en active Pending
- 2012-11-09 BR BR112014011229-0A patent/BR112014011229B1/pt active IP Right Grant
- 2012-11-09 CN CN201280066355.XA patent/CN104271745A/zh active Pending
- 2012-11-09 MX MX2014005653A patent/MX353189B/es active IP Right Grant
- 2012-11-09 CA CA2889659A patent/CA2889659C/en active Active
- 2012-11-09 JP JP2014540570A patent/JP6232544B2/ja active Active
- 2012-11-09 CN CN201711042348.7A patent/CN107875382B/zh active Active
2017
- 2017-08-04 JP JP2017151540A patent/JP6657150B2/ja active Active
- 2017-08-22 US US15/683,355 patent/US11248026B2/en active Active
2018
- 2018-05-18 AU AU2018203538A patent/AU2018203538A1/en not_active Abandoned
2020
- 2020-11-03 AU AU2020264275A patent/AU2020264275B2/en active Active
2022
- 2022-02-11 US US17/670,052 patent/US20230272013A1/en active Pending

Also Published As

Publication number	Publication date
RU2019139064A (ru)	2020-01-27
WO2013068847A3 (en)	2014-10-30
BR112014011229A2 (pt)	2017-05-09
JP2018023374A (ja)	2018-02-15
BR122019027913B1 (pt)	2021-11-30
AU2012335277B2 (en)	2018-06-14
CN107875382B (zh)	2024-03-08
DK2776567T3 (da)	2021-04-26
KR102301463B1 (ko)	2021-09-14
CN107875382A (zh)	2018-04-06
AU2012335277A1 (en)	2014-06-12
MX2014005653A (es)	2014-09-04
JP6232544B2 (ja)	2017-11-22
EP2776567B1 (en)	2021-01-20
CA2889659C (en)	2023-03-14
ES2874233T3 (es)	2021-11-04
KR20140095556A (ko)	2014-08-01
KR20190104644A (ko)	2019-09-10
WO2013068847A2 (en)	2013-05-16
CN111995664B (zh)	2024-08-02
CN104271745A (zh)	2015-01-07
AU2020264275B2 (en)	2023-12-14
US20140308308A1 (en)	2014-10-16
JP6657150B2 (ja)	2020-03-04
US11248026B2 (en)	2022-02-15
RU2737530C1 (ru)	2020-12-03
AU2020264275A1 (en)	2020-11-26
CA3166278A1 (en)	2013-05-16
CN111995664A (zh)	2020-11-27
EP2776567A2 (en)	2014-09-17
KR102340558B1 (ko)	2021-12-21
AU2018203538A1 (en)	2018-06-07
CA2889659A1 (en)	2013-05-16
MX353189B (es)	2018-01-05
US20230272013A1 (en)	2023-08-31
US20170349634A1 (en)	2017-12-07
EP3854416A1 (en)	2021-07-28
BR112014011229B1 (pt)	2021-10-13
EP2776567A4 (en)	2015-12-30
JP2015505299A (ja)	2015-02-19
US9777043B2 (en)	2017-10-03

Publication	Publication Date	Title
PT2776567T (pt)	2021-05-25	Composições e métodos para o tratamento de citomegalovírus
EP2771030A4 (en)	2015-07-22	COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
HK1210502A1 (en)	2016-04-22	Methods and compositions for treatment of a genetic condition
EP2603202A4 (en)	2016-06-01	COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
AP3965A (en)	2016-12-24	Anthelminitic compounds and compositions and method of using thereof
EP2675471A4 (en)	2015-01-28	HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2723384A4 (en)	2015-08-12	TREATMENT OF PROTEINOPATHIES
GB201110095D0 (en)	2011-07-27	Method of treatment
EP2773754A4 (en)	2015-06-10	Methods of Treatment
EP2717855A4 (en)	2014-11-12	PROCESSING METHODS
EP2675458A4 (en)	2014-08-06	COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
EP2887805A4 (en)	2016-08-17	COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
ZA201401653B (en)	2019-09-25	Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
ZA201404187B (en)	2019-10-30	Compositions and methods for treating dental conditions
EP2696874A4 (en)	2015-06-10	COMPOSITIONS AND METHODS USED TO TREAT NASAL CONDITIONS
HUE063599T2 (hu)	2024-01-28	Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére
IL228205B (en)	2020-02-27	Compositions and methods for treatment of intracellular damage
IL227924A0 (en)	2013-09-30	Preparations and methods of use for determining a4he
EP2670243A4 (en)	2014-06-18	COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLAUCOMA
EP2709999A4 (en)	2014-11-19	QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2725923A4 (en)	2015-05-27	EMULSIFYING COMPOSITIONS AND METHODS OF USING SUCH EMULSIFIABLE COMPOSITIONS
EP3603631C0 (en)	2023-11-29	METHOD AND COMPOSITIONS FOR THE TREATMENT OF DIVERTICULOSIS
EP2685820A4 (en)	2014-08-27	COMPOSITIONS AND METHODS FOR TREATING INFECTIONS
EP2791324A4 (en)	2015-04-29	PROCESSING METHOD
ZA201107399B (en)	2012-06-27	Method and compositions for treatment of cancer